In a patient with chronic rhinosinusitis who has persistent symptoms despite maximal medical therapy and evidence of type‑2 inflammation, what are the indications for initiating biologic therapy, which biologics are recommended, their dosing regimens, and how should response be monitored?

Biologics in Chronic Rhinosinusitis with Nasal Polyposis

Direct Recommendation

Dupilumab is the first-choice biologic for patients with chronic rhinosinusitis with nasal polyps (CRSwNP) who have failed maximal medical therapy and prior sinus surgery, with evidence of type 2 inflammation (blood eosinophils ≥150 cells/µL). 1

Indications for Initiating Biologic Therapy

Biologics should be initiated in patients with CRSwNP who meet the following criteria 1:

• History of prior endoscopic sinus surgery (failed surgical intervention)
• ≥3 of the following 5 criteria:
  • Evidence of type 2 inflammation (blood eosinophils ≥150 cells/µL)
  • Need for systemic corticosteroids or antihistamines
  • Significantly impaired quality of life
  • Significant loss of smell
  • Comorbid asthma

The 2025 EUFOREA guidelines lowered the blood eosinophil threshold from 250 to 150 cells/µL, expanding the eligible patient population 2. Patients with blood eosinophils ≥150 cells/µL demonstrate superior responses in nasal polyp score and nasal congestion compared to those with lower counts 3, though all patients show benefit.

Which Biologic to Choose

The 2025 EUFOREA pocket guide provides clear algorithmic guidance 1:

Primary Recommendations:

• Dupilumab (anti-IL-4Rα): First-line choice for CRSwNP
  • Shows most rapid and sustained improvement in nasal polyp score (significant from 4 weeks onward) 4
  • Superior improvement in olfactory function (anosmic patients decreased from 64.3% to 28.6% at 9 months) 4
  • At eosinophil counts ≥300 cells/µL, may be superior to anti-IL-5 agents for polyp reduction 3

Special Circumstances:

• Omalizumab (anti-IgE): First choice for females planning pregnancy in near future 1
• Mepolizumab (anti-IL-5): Consider in patients with comorbid highly eosinophilic asthma 1

Additional FDA-Approved Options:

The 2023 Joint Task Force guidelines note that multiple biologics targeting IL-4/IL-13 (dupilumab), IL-5 (benralizumab, mepolizumab, reslizumab), and IgE (omalizumab) are available 5. Tezepelumab (anti-TSLP) has also recently gained approval 6, 7.

Dosing Regimens

While specific dosing varies by agent and may be weight-based or fixed 5, the evidence supports:

• Standard dosing intervals: Follow manufacturer protocols initially
• Extended intervals: In well-controlled patients, longer administration intervals (every 4 weeks) have proven effective 2
• Administration: Parenteral (subcutaneous) via auto-injector or pre-filled syringe 1
• First 2 injections: Administer in hospital for training and monitoring for anaphylaxis risk 1
• Subsequent injections: Self-administration possible after training 1

Monitoring Response

Timeline for Assessment:

• Onset of effect: Weeks to months 1
• Initial evaluation: 6 months 2
• Ongoing monitoring: Annual follow-up 2

Response Categories (EPOS/EUFOREA 2023):

The updated guidelines simplified response assessment into three levels based on 2:

1. Reductions in nasal polyp size
2. Improvements in quality of life (SNOT-22 scores)
3. Enhancement of smell

Specific Outcome Measures:

• SNOT-22: All biologics show significant improvement from baseline to 9 months 4
• Nasal Polyp Score (NPS): Dupilumab shows earliest response (4 weeks), omalizumab and mepolizumab by 6 months 4
• Olfactory function: Sniffin' Sticks-12 testing 4
• Asthma Control Test (ACT): For patients with comorbid asthma 4

Additional Monitoring:

• Systemic corticosteroid use: Biologics significantly reduce need for rescue oral corticosteroids 1, 8
• Need for revision surgery: Should be markedly reduced 1, 8
• Comorbidities: Evaluate for eosinophilic otitis media, N-ERD (aspirin-exacerbated respiratory disease), atopic dermatitis, eosinophilic esophagitis 1

Critical Pitfalls and Caveats

Type 2 Inflammation Requirement:

Currently, biologics are indicated only for type 2 CRSwNP 1. Patients with non-type 2 inflammation respond poorly to current biologics 6. Confirm type 2 endotype through:

• Blood eosinophils ≥150 cells/µL (minimum threshold) 2
• Blood eosinophils ≥300 cells/µL identify superior responders 3
• Tissue eosinophilia on histology
• Elevated total IgE (for omalizumab consideration)

Treatment Duration:

Specific guidelines for discontinuation or switching biologics remain lacking 2. Clinical judgment is essential. Biologics do not cure the disease—they control inflammation while administered 1.

Cost Considerations:

Biologics are significantly more expensive than endoscopic sinus surgery, even accounting for revision procedures 7. In some countries (e.g., Korea), lack of insurance coverage necessitates extended dosing intervals 2.

Surgery vs. Biologics:

This is not an either/or decision—some patients benefit from combination therapy 7. Surgery does not modify underlying inflammation but augments medication delivery 7. Patients unable or unwilling to continue topical therapies may not benefit from surgery alone 7.

Pregnancy Planning:

Omalizumab has the most safety data in pregnancy, making it the preferred choice for women planning conception 1.

Missing Evidence:

• No validated biomarkers reliably predict which specific biologic will be superior for an individual patient 9
• Lack of head-to-head comparative trials between biologics 6, 2
• Optimal treatment duration undefined 6